kabutan

K Pharma,Inc.(4896) Summary

4896
TSE Growth
K Pharma,Inc.
694
JPY
-15
(-2.12%)
Jan 29, 3:30 pm JST
4.53
USD
Jan 29, 1:30 am EST
Result
PTS
outside of trading hours
Summary Chart Historical News Financial Result
PER
PBR
5.11
Yield
ー%
Margin Trading Ratio
Stock Price
Jan 29, 2026
Opening Jan 29, 9:00 am
709 JPY 4.63 USD
Previous Close Jan 28
709 JPY 4.64 USD
High Jan 29, 9:00 am
709 JPY 4.63 USD
Low Jan 29, 9:19 am
684 JPY 4.47 USD
Volume
35,700
Trading Value
0.03B JPY 0.16M USD
VWAP
691.25 JPY 4.52 USD
Minimum Trading Value
69,400 JPY 453 USD
Market Cap
8.06B JPY 0.05B USD
Number of Trades
125
Liquidity & Number of Trades
As of Jan 29, 2026
Liquidity
Slightly High
1-Year Average
516
1-Year High Mar 26, 2025
14,294
Margin Trading
Date Short Interest Long Margin Positions Ratio
Jan 23, 2026 0 336,900
Jan 16, 2026 0 332,500
Jan 9, 2026 0 367,200
Dec 26, 2025 0 363,800
Dec 19, 2025 0 352,600
Company Profile
K Pharma, Inc. engages in the research and development, manufacturing, and sales of pharmaceuticals and regenerative medicine products. The company originated from Keio University.
Sector
Pharmaceuticals
K Pharma, Inc. is a company specializing in the research and development, manufacturing, and sales of pharmaceuticals and regenerative medicine products. The company primarily focuses on the central nervous system disease area, developing both iPS cell-based drug discovery and regenerative medicine businesses. In iPS drug discovery, K Pharma is advancing the development of treatments for intractable diseases such as ALS and Alzheimer's disease. In regenerative medicine, the company is working on developing iPS cell-derived neural progenitor cell transplantation therapies for neurological disorders like spinal cord injury and cerebral infarction. Through collaborations with universities and research institutions, K Pharma commercializes basic research findings and has established a revenue model based on licensing agreements with pharmaceutical companies. The company aims for early clinical application, promoting the development of groundbreaking treatments in areas with high unmet medical needs.